AI Model Drift Becomes a Clinical Governance Test for Hospitals

Hospitals have spent the past several years learning how to buy artificial intelligence. Committees have been formed, risk assessments drafted, pilots run and vendors selected. The harder lesson is only now beginning. Once a model is embedded in a clinical workflow, the hospital inherits a responsibility that does not end at go-live: it must keep deciding whether the tool is still performing as intended.

That responsibility is becoming more visible because AI in healthcare is no longer confined to experimental projects. Tools that flag deteriorating patients, draft documentation, triage imaging and support coding are moving into routine use. Each was validated against a particular version of a hospital's data, workflows and patient population. Those conditions do not hold still, and as they change, model performance can change with them.

The result is a governance problem rather than a procurement one. The question for hospital boards is no longer simply whether a tool was approved, but whether anyone can demonstrate, months or years later, that it remains safe where it is actually used. That shift from acquisition to stewardship sits close to the concerns recognised through the 2026 Global Healthcare Awards, where credible innovation is judged alongside accountability for its effects.

Why performance does not stay fixed

A clinical AI model is not a piece of equipment with a fixed output. It is a statistical pattern learned from historical data, and its usefulness depends on the world continuing to resemble that data. In hospitals, the world rarely cooperates. Patient mix is one source of change: a model trained when a hospital served a particular population may behave differently after a service reconfiguration, a merger or a shift in case severity. Documentation practices matter too, because if clinicians enter information in a different structure or with different terminology, the inputs a model relies on may become less reliable. Equipment changes can alter the images or signals a tool receives, and even an upgrade to the electronic health record can disturb a model's data feed.

These shifts are usually gradual. A model may continue producing outputs that look plausible while its accuracy quietly erodes, or while its alerts concentrate on patients who turn out not to need attention. Clinicians may respond by ignoring the tool, which creates a second problem: a system nominally in use but no longer meaningfully informing care.

The gap between approval and accountability

Regulatory clearance and vendor validation answer a narrow question: whether a product met a defined standard at a point in time, for an intended use. They do not certify that the tool performs well in a specific hospital, with that hospital's data, staff and case mix, over the years that follow.

This is where governance gaps appear. A hospital may have a rigorous approval process that ends abruptly at deployment. Responsibility for ongoing review is often assumed rather than assigned. Informatics teams may believe clinical leadership owns the question; clinical leaders may assume the vendor monitors performance; procurement may treat the contract as complete once the system is live. Risk and safety teams may only encounter the tool after an incident.

The gap widens when AI is treated as a static product rather than an evolving clinical system. Static products are bought, installed and maintained on a schedule. Evolving systems need owners, indicators, review cycles and a route for escalation. Without those arrangements, a hospital can hold a complete approval file and still be unable to answer a basic board question: how do we know this is working as expected?

What practical monitoring looks like

Effective post-deployment oversight does not require a large new department. It requires a small number of deliberate arrangements, clearly owned and routinely reviewed.

• Defined performance indicators. Each tool should have a short set of measures agreed before deployment, covering technical behaviour and clinical consequence: alert volumes, the proportion of alerts acted upon, override rates and any available outcome measures. The aim is to notice change, not to prove perfection.
• Incident reporting that captures AI-related harm. Existing safety systems should let staff flag concerns about a tool's output, not only obvious failures. A clinician who distrusts a recommendation needs a route to say so that reaches someone able to act.
• Audit trails and version records. Hospitals should be able to establish which version of a model was running at a given time, what inputs it received and what it recommended. This matters for investigation and accountability.
• Periodic clinical review. A scheduled review involving clinicians who use the tool, informatics staff and safety leads gives drift a forum. It should consider whether the tool still fits the workflow and whether local conditions have shifted.
• Documented decisions. When a hospital adjusts thresholds, restricts use or withdraws a tool, the reasoning should be recorded. Decisions taken informally are difficult to defend.

These mechanisms work best when they are proportionate. A documentation assistant and a deterioration-prediction tool carry different risks and warrant different levels of scrutiny. What matters is that oversight is chosen deliberately rather than inherited by accident.

Contract terms that support stewardship

Much of a hospital's ability to monitor performance is settled at the contracting stage, which gives procurement teams a direct stake in questions that can appear technical or legal.

Contracts can specify what performance information a vendor will provide after deployment, how often and in what form. They can require advance notification of model updates or changes to underlying data sources, since an unannounced update can alter behaviour in ways local teams have not assessed. They can clarify responsibility when a tool contributes to a safety event, and set out what happens to data and documentation if the relationship ends. Exit provisions deserve particular attention: a hospital that cannot retrieve its data, or revert to a prior workflow, has limited practical leverage.

A shared accountability model

The most common failure in AI governance is fragmentation. Clinical leadership, informatics, risk, procurement, pharmacy and nursing each hold part of the picture, and no one holds the whole. Approval processes that sit in a single committee can reinforce that separation.

A more durable model assigns named ownership for each deployed tool, with a defined group — spanning clinical safety, informatics, procurement and frontline users — that reviews performance on a regular cycle and has the authority to change or stop use. That group needs a route to the board, because decisions about withdrawing a tool or accepting a known limitation are governance decisions, not merely technical ones.

None of this diminishes the value of healthcare AI. It reflects a maturing understanding that the technology's benefits depend on the arrangements around it. As adoption deepens, the institutions that stand out will not simply be those that adopted earliest, but those that can show, with evidence and clear accountability, that their systems continue to work safely as everything around them changes. That is the standard the 2026 Global Healthcare Awards seeks to recognise: innovation that can be defended long after the pilot has ended.